Shows
Base to Base BiotechBase to Base biotech podcast 11: Turning cancer into a chronic disease, and a different way to draw bloodThis week, we have a conversation with Ben Zeskind, CEO and co-founder of Immuneering, and a discussion with Tasso Inc.’s co-founder and chief technology officer, Erwin Berthier.Interview times:01:27 Tasso27:25 ImmuneeringImmuneeringThere is no cure for HIV, yet many people with the virus now live long, healthy lives – thanks to available medicines that prevent disease progression with minimal side effects, treating HIV almost like a chronic condition.So why don’t we treat cancer the same way?Curing cancer is seen as the gold s...2025-05-3054 min
MedCity PivotReimagining Cancer Treatment with Ben ZeskindI interviewed the CEO of Immuneering and talked with him about how traditional approaches toward treating certain cancers may be missing the mark in terms of not only survival but also quality of life. Episode Resources Connect with Arundhati Parmar aparmar@medcitynews.com https://twitter.com/aparmarbb?lang=en https://medcitynews.com/ Connect with Ben Zeskind https://www.linkedin.com/in/bzeskind Review, Subscribe and Share If you like what you hear please leave a review by clicking here Make sure you’re subscribed to the podcast so you get the latest epis...2025-04-2327 min
Business Of Biotech004: Finding Funding In Volatile Times With Dr. Ben ZeskindWe love to hear from our listeners. Send us a message. This week's Business Of Biotech pod features Immuneering CEO Dr. Ben Zeskind, who launched his biotech on the back of creative financing in the throes of the Great Recession. A pivot into biopharma landed Immuneering a $20 million series A round to develop its pipeline--at the outset of the COVID-19 pandemic. Dr. Zeskind joins us for a candid and instructive discussion on getting creative when the economy isn't exactly booming. Access this and hundreds of episodes of the Business of Biotech videocast under t...2020-06-0135 min
The Bio ReportReversing Disease SignalsBen Zeskind likens Immuneering’s platform technology to noise-cancelling headphones. Infact, the company’s use of the term “Disease Cancelling Technology” speaks directly to that. The approach, he says, allows the company to build a pipeline of drug candidate that address aspects of disease that have eluded tradition drug development approaches. We spoke Zeskind, CEO of Immuneering, about the company’s evolution from its roots in bioinformatics, its movement into drug development, and how its proprietary platform technology works.2020-01-1631 min
The Bio ReportReversing Disease SignalsBen Zeskind likens Immuneering’s platform technology to noise-cancelling headphones. Infact, the company’s use of the term “Disease Cancelling Technology” speaks directly to that. The approach, he says, allows the company to build a pipeline of drug candidate that address aspects of disease that have eluded tradition drug development approaches. We spoke Zeskind, CEO of Immuneering, about the company’s evolution from its roots in bioinformatics, its movement into drug development, and how its proprietary platform technology works.2020-01-1631 min